unaudited consolidated financial results for the quarter ended
The announcement will be followed by a conference call and webcast with
update and review first quarter financial results.
To access the conference call via telephone, please dial (877) 412-6083
telephone replay will be available from approximately
the conference call, dial (855) 859-2056 from
537-3406 for international access. The pass code for the live call and
the replay is 37544923.
The call will be webcast with slides and accessible through the
Investors section of the company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 7:30 p.m.
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.
Feraheme is a registered trademark of
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303